VLUXE Investments retweeted
Adani Defence & Aerospace successfully demonstrated Bagheera AT1, a vehicle-mounted anti-tank guided missile (ATGM) system, at the Pokhran Field Firing Ranges in Rajasthan.
Bagheera AT1 is the outcome of 18 months of design and development, during which the missile system was customised for Indian terrain, climate and operational requirements. It is a complete combat system comprising the missile, automated launcher and day and night sights, mounted on an Adani Defence-designed 4x4 high-mobility armoured vehicle.
Four anti-tank missiles were successfully fired during the demonstration.
Key capabilities of Bagheera AT1:
- Anti-tank engagement range of 8 km, with the wider missile architecture capable of supporting guided engagements of up to 10 km.
- Laser beam-riding guidance, highly resistant to electronic jamming.
- Two-missile salvo on a single beam, designed to defeat a tank’s active protection system.
The No Cost No Commitment (NCNC) demonstration on 20 November was witnessed by senior representatives of the Indian Army, Department of Military Affairs and Ministry of Defence (MoD).
@AdaniDefence
VLUXE Investments retweeted
The Indian Government and Indian Armed Forces are supporting drone technology. But unfortunately, our own units keep ordering Chinese drones and parts on GeM.
We reviewed GeM tenders from 10 March 2021 to 19 November 2026. Here is what we found. 🧵 1/7
🏥 Star Imaging and Path Lab Ltd: H1 Revenue +8%, PAT Falls 22%; Targets 20-25% Growth & 30-35% EBITDA Margin
👉🏻 H1 FY27: Revenue ₹48.9 Cr (+8% YoY); Op EBITDA ₹14.1 Cr (−18.5%), margin 28.9% vs 38.2% YoY; PAT ₹7.8 Cr (−22%), margin 16%.
👉🏻 Business Growth: B2B revenue +20% and B2C +21%, together contributing 48% of revenue. B2G remained broadly flat.
👉🏻 Expansion: Added 40-45 hospitals, taking partnerships to 150+. Network at 26 diagnostic centres, with 30% spare capacity for higher utilisation.
👉🏻 New Dwarka Centre: CT, MRI, ultrasound and X-ray facility targeting commissioning by November-end, subject to approval. Expected ₹5-6 Cr first-year revenue, with breakeven within 12 months.
👉🏻 PPP Pipeline: Three government diagnostic projects allotted, with MoU signing pending. Expanding MRI capacity at Tilak Nagar and developing genome-sequencing capabilities.
👉🏻 Cash Flow Concern: Receivables rose to ₹64 Cr from ₹49.9 Cr in March; H1 OCF was −₹6.2 Cr. Around ₹15 Cr relates to legacy COVID-period government dues. Management targets cash-flow neutrality by FY27-end.
👉🏻 H2 Outlook: Management indicated ~₹60–65 Cr revenue, mainly driven by B2B/B2C expansion and new centres. FY27 capex planned at ₹20–25 Cr.
👉🏻 Medium-Term Guidance: Targets 20-25% revenue growth, 30-35% EBITDA margin and 20% PAT margin over 2-3 years, supported by hospital partnerships, PPP projects and specialised diagnostics.
#STARIMAGIN #StarImaging #Diagnostics #Healthcare #H1Results
624
🏥 Gaudium IVF & Women Health Ltd: Q2 Revenue +18%, Core IVF +22%; Maintains ₹130 Cr FY27 Target, Eyes 25% Annual Growth
👉🏻 Q2 FY27: Revenue ₹37.4 Cr (+17.9% YoY); Op EBITDA ₹13.5 Cr, margin 36% vs 43.4% YoY; PAT ₹9.4 Cr, broadly flat YoY.
👉🏻 H1 FY27: Revenue ₹56.8 Cr (+14.7% YoY); EBITDA ₹15.9 Cr vs ₹19 Cr; PAT ₹11.2 Cr vs ₹12.5 Cr. Margins impacted by new-centre rollout and marketing expenses.
👉🏻 Core IVF Growth: Standalone IVF revenue ₹28.1 Cr (+22.3% YoY) in Q2. Established Delhi, Mumbai and Bengaluru centres grew ~28%; 889 egg-retrieval cycles completed during Q2.
👉🏻 Expansion: Opened South Extension and Gurugram hubs; network now 9 hubs and 38 spokes. Nagpur awaiting approval; Lucknow, Kolkata, Guwahati, Surat and Hyderabad identified for expansion.
👉🏻 New Hub Economics: Average investment ₹2.5 Cr per hub; breakeven targeted within 3–6 months, with 1.5-2-year capex payback. South Extension nearly broke even within 2.5 months.
👉🏻 Clinical Performance: Management reports 62% first-attempt clinical pregnancy rate, up from 56% before introducing AI-assisted embryology tools SiD and ERICA.
👉🏻 Working Capital: Consolidated receivables declined to ₹45.3 Cr from ₹53.37 Cr in March, but collection cycle remains elevated at 165 days. Borrowings ₹4.8 Cr; debt/equity 0.03x.
👉🏻 FY27 #Outlook: Maintains ₹130 Cr revenue guidance, expecting a substantially stronger H2, with Q4 seasonally strongest. Management aims to restore historical margins by year-end despite rollout costs.
👉🏻 FY28-29 #Growth: Management indicated ~25% annual revenue growth aspiration, supported by new hub openings, higher patient volumes and operating leverage as centres mature.
👉🏻 Further #Expansion: Planned Lucknow women's hospital with investment up to ₹15 Cr, targeting commercialisation in FY29.
#GAUDIUMIVF #GaudiumIVF #FertilityCare #Healthcare #Q2Results
3
770
VLUXE Investments retweeted
Four successful firings at Pokhran. One formidable leap for India’s anti-armour capabilities. Bagheera AT1 delivers precision, versatility and readiness. 🇮🇳
#AdaniDefence #AatmanirbharBharat
VLUXE Investments retweeted
China Actively Undercuts India’s Efforts to Break Upstream Dependency in Pharmaceutical Industry: US report
💎 Senco Gold Ltd: Q2 Revenue +34%, H1 +52%; Festive Sales ₹2,400 Cr, Targets ₹20,000 Cr Revenue by FY30
👉🏻 Q2 FY27: Revenue +34% YoY; EBITDA margin 4.4%, pressured by discounts, old-gold exchanges and franchise sales. PAT margin 4.1%, supported by hedging gains.
👉🏻 H1 FY27: Revenue crossed ₹5,000 Cr (+52% YoY); PAT ₹188 Cr (+22%); EBITDA margin 7.6%, including ~90 bps benefit from customs-duty gains. TTM sales exceeded ₹10,000 Cr.
👉🏻 Retail Growth: Q2 retail sales +29%; same-store sales growth 19%. Old-gold exchanges exceeded 51% of business, impacting margins by 20-40 bps.
👉🏻 Festive Performance: Sales of ₹2,400 Cr (+25-26% YoY) during Oct 1-Nov 11; same-store growth 17%, diamond jewellery +26%.
👉🏻 Store Expansion: Opened 24 stores in FY27 so far, surpassing the initial 18-20 target. Another 3-4 openings planned over the coming months.
👉🏻 Profitability: Q2 other income benefited from substantial hedging gains, partly offsetting operating-margin pressure. Management maintains 7.5-7.8% EBITDA margin objective, expecting Q3 recovery.
👉🏻 Near-Term Outlook: Management expects 25%+ revenue growth in Q3 and 20%+ in Q4, supported by festive momentum, weddings and continued store expansion.
👉🏻 FY30 Vision: Targets ₹20,000 Cr revenue, ~8% EBITDA margin and 15% studded-jewellery mix, driven by new stores, higher existing-store productivity and diamond/lightweight jewellery.
👉🏻 Long-Term Growth: Management models 15-16% sustainable annual growth under stable gold prices, including 10-12% same-store growth.
#SENCO #SencoGold #JewelleryRetail #GoldJewellery #Q2Results
1
778
🚛 Ashok Leyland Ltd: Targets Mid-Teen EBITDA Margins Over Medium Term
👉🏻 Record Sales: Domestic CV volumes 59,575 units (+34% YoY); M&HCV +44%, outperforming industry growth of 39%. M&HCV market share rose 120 bps to 32.1%; LCV volumes +21% to 21,371 units.
👉🏻 Other Businesses: Defence revenue ₹400 Cr (+66% YoY); Power Solutions +33%; domestic aftermarket +20%. Export volumes +7%, despite West Asia disruptions.
👉🏻 Margin Pressure: Material costs rose 340 bps QoQ to 74.9% of revenue, driven by steel, rubber and fuel inflation. Management is pursuing 1-1.5% price increases in Q3, with further recovery possible in Q4.
👉🏻 Balance Sheet: Net cash surplus ₹3,546 Cr, up ₹2,556 Cr YoY. FY27 capex planned at ₹1,000-1,200 Cr. Interim dividend ₹1/share.
👉🏻 EV Expansion: Switch Mobility delivered 439 e-buses and 732 electric LCVs in H1; order book ~2,800 e-buses. New 4 GWh battery-pack plant targeted for Q3 FY28 production, expandable to 8-12 GWh.
👉🏻 Capacity & Products: Plants operating near 90% utilisation; debottlenecking and greenfield expansion planned. New HIPPO, TAURUS and air-suspension trucks supporting premiumisation and market-share gains.
👉🏻 Industry Outlook: Management expects double-digit to mid-teen FY27 CV industry growth, with stronger GCC exports in Q3-Q4 as logistics normalise.
👉🏻 Margin Outlook: Maintains mid-teen EBITDA margin aspiration over the medium term, although commodity inflation may keep near-term margins under pressure.
👉🏻 HLF Merger: NCLT approval received for merger with NDL Ventures. Auditors flagged unreconciled loan-balance discrepancies; independent review underway, with financial impact not yet ascertainable.
#ASHOKLEY #AshokLeyland #CommercialVehicles #ElectricMobility #Q2Results
Ashok Leyland Ltd
➡️Dividend: ₹1 (RD: 20th Nov)
➡️OCF (H1FY27): -₹1,695.7 Cr vs -₹5,147.8 Cr (YoY)
News: t.me/VLuxeLive
IG: instagram.com/vluxeinvests
TG: t.me/vluxeinvests
#Q2FY27 #Q2FY27Results #Q2Results #ASHOKLEY
637
VLUXE Investments retweeted
*ANTHROPIC IPO SAID TO DRAW ABOUT $115B-$120B OF RETAIL DEMAND
And you will never guess what happened the next day...
💊 Jubilant Pharmova: Q2 Revenue +21%, EBITDA ₹255 Cr; Targets Mid-Teen EBITDA Margin in H2 FY27
👉🏻 Q2 FY27: Revenue ₹2,370 Cr (+21% YoY); Op EBITDA ₹255 Cr, margin 10.8%; PAT ₹31 Cr.
👉🏻 H1 FY27: Revenue ₹4,599 Cr (+19% YoY); EBITDA ₹523 Cr, margin 11.4%; PAT ₹87 Cr.
👉🏻 #Radiopharma: Ruby-Fill growing 30-35% annually. Announced C$94.5 Mn capacity expansion, with C$23.8 Mn government support; commissioning targeted for H2 FY29. SPECT supply recovery expected to support margins, particularly in Q4 FY27.
👉🏻 Montreal Challenge: Facility recorded ₹80 Cr+ loss in Q2 and ~₹157 Cr in H1 due to remediation costs and low utilisation. Management expects lower losses in H2, but regulatory remediation remains ongoing.
👉🏻 Sterile Injectables: Spokane Line 3 generated ~$20 Mn Q2 revenue, with 13+ tech transfers underway. Targets $80-90 Mn annual peak revenue, with improving margins in FY28 and more substantial gains in FY29 as commercial production scales.
👉🏻 Expansion Pipeline: Line 4 has 23 active customer proposals, with tech transfers targeted from Q4 FY27. Six new PET radiopharmacies planned to begin operations progressively from Q3 FY28.
👉🏻 Generics: Growth supported by new launches and market-share gains. Targets 6-8 launches annually, with long-term ambition to double revenue and achieve 15-17% EBITDA margin.
👉🏻 Drug Pipeline: MIBG NDA filing targeted for Q4 CY27/early CY28. JBI-802 remains in Phase 1/2 trials, with further clinical data expected in December 2026.
👉🏻 H2 #Outlook: Management expects revenue growth momentum to continue and EBITDA margins to improve sequentially, targeting mid-teen average margins in H2 FY27.
👉🏻 #Capex & Debt: FY27 capex ₹1,800-1,900 Cr, reducing to ₹1,000 Cr in FY28. Net debt expected near ₹4,000 Cr by FY27-end, with zero net debt targeted by FY30.
#JUBLPHARMA #JubilantPharmova #Radiopharma #CDMO #Q2Results
651
🏭 Belrise Industries: Record Q2 PAT ₹166 Cr (+25%); Manufacturing Revenue +26%, Enters Global Smartphone Supply Chain
👉🏻 Q2 FY27: Revenue ₹2,746 Cr (+17% YoY); Op EBITDA ₹331 Cr (+12%), margin 12%; adjusted PAT ₹166 Cr (+25%).
👉🏻 Manufacturing: Revenue ₹2,344 Cr (+26% YoY); EBITDA ₹317 Cr (+19%), margin 13.5%. H1 manufacturing revenue ₹4,542 Cr (+23%).
👉🏻 Consumer Electronics: Secured maiden precision-tooling order in a major US smartphone manufacturer's ecosystem. Initial order small, but management sees significant recurring opportunities in CNC, MLB and assembly-testing fixtures.
👉🏻 CV Expansion: New Dharwad plant to supply complete chassis assemblies, targeting ₹150-200 Cr annual revenue at peak capacity. Production ramp-up from Q1 FY28.
👉🏻 3W Expansion: New complete body-and-chassis assembly facility in Sambhajinagar, targeting ₹100-120 Cr annual revenue at peak capacity from Q1 FY28.
👉🏻 #Aerospace: UK subsidiary Chester Hall secured additional aircraft-engine nacelle track-beam orders with higher volumes and pricing. Management targets aerospace and defence exceeding 10% of manufacturing revenue over 12-18 months.
👉🏻 New Business: Maiden sheet-metal orders from Japanese and European passenger vehicle OEMs. Proprietary suspension business expanded to 6 OEM customers; exclusive Yamato technology partnership for filters and resin intake manifolds.
👉🏻 Growth #Outlook: Management maintains mid-teens revenue growth guidance with stable EBITDA margins. Automotive growth, aerospace, electronics and renewables expected to drive expansion.
👉🏻 Returns: ROCE improved to 15.3% (+60 bps YoY), excluding unutilised QIP proceeds. Management targets high-teens ROCE over the next few years, supported by higher utilisation and proprietary products.
#BELRISE #AutoComponents #Aerospace #Q2Results
Belrise Industries Ltd
➡️OCF (H1FY27): ₹491.2 Cr vs ₹55 Cr (YoY)
News: t.me/VLuxeLive
IG: instagram.com/vluxeinvests
TG: t.me/vluxeinvests
#Q2FY27 #Q2FY27Results #Q2Results #BELRISE
1
809
🏭 Alicon Castalloy: Record Q2 Revenue +50%, PAT +27%; ₹6,700 Cr Order Book, Targets 12-15% Alloy-Adjusted FY27 Growth
👉🏻 Q2 FY27: Total income ₹652 Cr (+50.4% YoY, +12.6% QoQ); Op EBITDA ₹65.3 Cr (+14% YoY, +18% QoQ), margin 10%; PAT ₹17.6 Cr (+27% YoY).
👉🏻 H1 FY27: Total income ₹1,231 Cr (+44% YoY); EBITDA ₹120.6 Cr (+11%), margin 9.8%; PAT ₹29.1 Cr (+25%).
👉🏻 Underlying Growth: Excluding aluminium price inflation, Q2 revenue grew 24% YoY; tonnage +19.3% and value addition +22%. CV cylinder-head share increased from ~13% to 23% in H1.
👉🏻 #OrderBook: ₹6,700 Cr executable through FY32. Q2 wins across 8 components from 3 customers, with ₹270 Cr potential annual peak revenue; 70% volume ramp expected by FY29.
👉🏻 New Programs: 25-30 components expected to enter production over the next year. Major hybrid-vehicle win expected to double existing hybrid revenue; additional PV, CV and EV programs progressing.
👉🏻 #CapEx: New Pune plant adding 12,000 tonnes/year, with mass production targeted for April 2027. Management expects ₹120-150 Cr revenue in its first year. FY27 capex ₹150 Cr.
👉🏻 Exports & Diversification: Export revenue share targeted to rise from 13% to 18-20% by FY27-end. Data-centre cooling business targets ₹15-20 Cr FY28 revenue; new tractor components ₹12-15 Cr annually.
👉🏻 Margin Outlook: Management targets ~12% alloy-adjusted EBITDA margin in FY27, with ~100 bps annual improvement and 14-15% margin ambition by FY30. Slovakia operations expected to turn EBITDA-positive in FY28.
👉🏻 Growth Guidance: Reiterates 12-15% alloy-adjusted FY27 revenue growth and 15%+ annual tonnage growth. Q3 expected seasonally softer, followed by stronger Q4 execution.
#ALICON #AliconCastalloy #AutoComponents #Manufacturing #Q2Results
706
🏭 Simplex Castings: Record Q2 PAT +37%, EBITDA +32%; Targets ₹300 Cr+ FY27 Revenue & ₹500 Cr in FY28
👉🏻 Q2 FY27: Revenue ₹63.01 Cr (+13.7% YoY); Op EBITDA ₹12.75 Cr (+32.1%), margin 20.23% (+282 bps); PAT ₹7.64 Cr (+37%), highest-ever quarterly profit.
👉🏻 H1 FY27: Revenue ₹123.96 Cr (+23.2% YoY); EBITDA ₹24.26 Cr (+29.1%); PAT ₹14.5 Cr (+40.6%), margin 11.7%.
👉🏻 Growth Guidance: Management maintains ₹300 Cr+ FY27 revenue target and ₹500 Cr for FY28. H2 execution expected to accelerate, with margins broadly similar to H1.
👉🏻 Order Visibility: ₹150 Cr pending order book, largely executable in FY27, plus ₹100 Cr+ pipeline. Major demand from steel, thermal power and railway projects.
👉🏻 Capacity Expansion: ₹25 Cr capex to increase monthly heavy-structure fabrication from 500 to 1,500 tonnes and equipment capacity from 200 to 300–350 tonnes. Full commissioning targeted by Q1 FY28.
👉🏻 Steel & Power: Management estimates 90–95% share in domestic coke-oven-door projects. Targeting ~₹120 Cr from upcoming coke-oven batteries and ₹150 Cr+ annual heavy-fabrication revenue from power projects.
👉🏻 Railway Opportunity: RDSO approval secured for cast bogies, but major wagon orders remain delayed. Developing fabricated bogies, couplers and other components; targeting railways at 30–40% of business over 2–3 years.
👉🏻 Funding & Margins: ~₹100 Cr fundraise approved, primarily supporting working capital and existing capex. Management targets 8–10% sustainable PAT margin, cautioning that Q2's 12.13% is unusually high.
#SimplexCas #SteelIndustry #PowerInfra #Railways #Q2Results
633
🏭 Ipca Laboratories to Close Mahad Drug Intermediates Unit; Agrees ₹16.90 Cr Property Sale
👉🏻 Buyer: ICMC Corporation Ltd.
👉🏻 Assets: 25,138 sq. metres leasehold land and existing factory structures at Mahad, Maharashtra.
👉🏻 Book Value: ₹13.21 Cr for assets proposed to be sold.
👉🏻 Operations: Intermediate production shifted to other plants; machinery to be transferred.
👉🏻 Completion: Targeted by 31 March 2027, subject to approvals.
#IPCALAB #Pharmaceuticals #AssetSale #Manufacturing #CorporateRestructuring
1
589
⚙️ Kirloskar Brothers Ltd & JV Secure ₹366 Cr Pump Orders for Dangote Refinery, Nigeria
👉🏻 Client: Dangote Petroleum Refinery & Petrochemicals, Lagos.
👉🏻 Combined Orders: US$38.94 Mn (~₹366 Cr).
👉🏻 KBL Share: US$17.60 Mn (~₹165 Cr).
👉🏻 JV Share: Kirloskar Ebara Pumps — US$21.34 Mn (~₹201 Cr).
👉🏻 Project: Pumping solutions for refinery with 7 lakh barrels/day refining capacity.
#KIRLOSBROS #DangoteRefinery #Nigeria #IndustrialPumps #OrderWin
581
💊 Cohance Lifesciences Receives USFDA VAI Classification for Shamshabad Formulation Facility
👉🏻 Facility: Finished Dosage Formulations plant, Shamshabad, Telangana.
👉🏻 Outcome: USFDA issues Establishment Inspection Report (EIR).
👉🏻 Classification: Voluntary Action Indicated (VAI).
👉🏻 Status: Inspection concluded; no further inspection outcome pending.
#COHANCE #USFDA #VAI #Pharmaceuticals
542
🧲 Permanent Magnets to Inaugurate NdFeB Rare Earth Magnet Manufacturing Facility on 8 Dec 2026
👉🏻 Subsidiary: Quantum Magnetics Pvt Ltd, wholly owned.
👉🏻 Location: Vasai, Maharashtra.
👉🏻 Products: Neodymium-Iron-Boron (NdFeB) permanent magnets.
👉🏻 Applications: Electric vehicles, renewable energy, electronics and industrial equipment.
👉🏻 Capacity & Investment: Undisclosed.
#PERMAGN #RareEarth #NdFeB #ElectricVehicles #Manufacturing
554
💊 Aurobindo Pharma's Apitoria Unit-VI Receives USFDA VAI Classification; Inspection Closed
👉🏻 Facility: API manufacturing unit at Parawada, Andhra Pradesh.
👉🏻 Inspection: 24–28 August 2026.
👉🏻 Observations: Three USFDA observations.
👉🏻 Outcome: Establishment Inspection Report received with Voluntary Action Indicated (VAI) classification.
👉🏻 Status: USFDA confirms inspection closure.
#AUROPHARMA #USFDA #VAI #Pharmaceuticals #RegulatoryUpdate
595
☀️ Waaree Energies Ltd Signs 700 MW Solar + 2,800 MWh Battery Storage PPA With SECI
👉🏻 Offtaker: Solar Energy Corporation of India Ltd.
👉🏻 Subsidiary: Waaree Forever Energies Pvt Ltd.
👉🏻 Project: 700 MW solar power with 700 MW/2,800 MWh energy storage.
👉🏻 Location: Solapur, Maharashtra.
👉🏻 Status: PPA executed on 20 November 2026; commercial terms undisclosed.
#WAAREEENER #SECI #SolarEnergy #BatteryStorage #PPA
594
🏭 Sugs Lloyd Secures ₹16.54 Cr Industrial Land Allotment in Noida for Electrical Equipment Manufacturing
👉🏻 Authority: NOIDA Industrial Development Authority.
👉🏻 Land: 3,342 sq. metres at Sector 162, Noida.
👉🏻 Consideration: ₹16.54 Cr plot premium through e-auction.
👉🏻 Purpose: Establish manufacturing facility for electrical goods.
👉🏻 Status: Allotment letter received; facility development proposed.
#SUGSLLOYD #Noida #ElectricalEquipment #Manufacturing #Expansion
3
687



















